Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Planar catechin is a synthetic catechin analogue in which the catechol and chroman moieties of natural (+)-catechin are constrained to be coplanar, resulting in a "planar" structure. This modification results in **significantly higher antioxidant activity**—approximately 5 to 10 times greater radical-scavenging ability than native catechin—owing to increased electron delocalization. Planar catechin demonstrates enhanced protection against oxidative DNA damage, efficient free radical scavenging (notably DPPH), and less pro-oxidant activity compared to catechin[1][2][3][5][7]. Notably, it also exhibits **anti-cancer properties**, selectively inducing cytotoxicity in cancer cells—mainly through a decrease in mitochondrial membrane potential and induction of mitochondrial dysfunction—while showing lower toxicity to normal cells[2][3][4][6]. Other reported bioactivities include \u03b1-glucosidase inhibition, anti-viral effects, inhibition of amyloid \u03b2 aggregation, and radioprotective properties[5][7]. The primary mechanism of action is ROS (reactive oxygen species) scavenging, likely mediated through both direct antioxidant effects and disruption of mitochondrial ROS signaling pathways in cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on planar catechin.